ARA290: Preclinical Research on Inflammation and Repair

Disclaimer: All articles and product details provided on this website are intended for educational and informational purposes only. The products listed here are for in-vitro research only. In-vitro studies are conducted outside of living organisms. These products are not intended as medicines or drugs and have not been approved by the FDA to prevent, treat, or cure any medical condition, ailment, or disease. The direct or indirect administration of these substances to humans or animals is unequivocally prohibited under applicable law.

ARA290 and Protection Against Renal Injury

Preclinical data demonstrate that ARA290 significantly mitigates cisplatin-induced nephrotoxicity. It reduced DNA fragmentation (comet assay), minimized micronucleus formation, and alleviated oxidative stress by lowering ROS/MDA levels while enhancing antioxidant enzyme activity. Treatment was associated with decreased pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), reduced apoptotic mediators (Caspase-3, Bax), and increased expression of the anti-apoptotic protein Bcl-2. Collectively, these findings suggest that ARA290 exerts renoprotective effects by attenuating inflammation, limiting oxidative injury, and preserving cell survival.

ARA290 in Wound Repair and Diabetic Healing

Diabetic foot ulcers remain a major clinical challenge due to delayed healing and infection risk. The innate repair receptor (IRR), which is activated by erythropoietin-derived pathways, plays a role in tissue recovery. Studies on streptozotocin-induced diabetic models have shown that topical ARA290 accelerates wound closure, shortens re-epithelialization time, and increases collagen and protein deposition in healing tissue. Treatment also improved systemic markers, including higher serum insulin and HDL, alongside reductions in glucose and lipid levels.

Animals treated with 10% and 20% topical ARA290 showed accelerated contraction and epithelialization compared with diabetic controls. Collagen and protein levels were markedly improved, highlighting enhanced structural repair.

Cardiovascular and Aging-Related Findings

In aged rat models, ARA290 improved left ventricular function, reduced myocardial inflammation, and supported mitochondrial homeostasis. Notably, treatment reduced frailty, a clinical state of systemic vulnerability, and prolonged healthspan beyond midlife. Rats receiving ARA290 maintained body weight stability later in life, with attenuated age-related decline.

Mechanistically, ARA290 enhanced cardiomyocyte autophagic flux, preserved mitochondrial protein turnover, and reduced accumulation of lipofuscin, an age-associated byproduct of impaired proteostasis. These findings indicate that chronic ARA290 administration sustains cardiac function, supports mitochondrial health, and mitigates systemic frailty in advanced age.

Broad-Spectrum Anti-Inflammatory Activity

ARA290 acts through selective IRR activation, initiating signaling pathways that suppress apoptosis, enhance cell survival, and stimulate nitric oxide production within endothelial tissue. These mechanisms reduce tissue inflammation and promote repair. Experimental data show that ARA290 decreases lipid peroxidation while restoring antioxidant enzyme activity (SOD, CAT, GPx, GST) in diabetic models. Pro-inflammatory markers including NF-κβ, TNF-α, IL-6, and IL-10 were also significantly reduced following treatment.

This broad anti-inflammatory profile underscores its role not only in organ-specific injury prevention but also in systemic tissue protection.

Influence on Glucose Regulation and Lipid Metabolism

In diabetic models, ARA290 administration lowered hyperglycemia, restored insulin levels, and improved lipid profiles. Significant reductions in total cholesterol, triglycerides, and LDL were observed, alongside increased HDL levels.

Conclusion

Through its anti-inflammatory, antioxidant, and anti-apoptotic mechanisms, ARA290 enhances tissue repair, preserves mitochondrial integrity, and reduces systemic frailty. Much of the current evidence derives from preclinical studies.

REFERENCES

1. Ghassemi-Barghi, N., Ehsanfar, Z., Mohammadrezakhani, O. et al. Mechanistic Approach for Protective Effect of ARA290, a Specific Ligand for the Erythropoietin/CD131 Heteroreceptor, against Cisplatin-Induced Nephrotoxicity, the Involvement of Apoptosis and Inflammation Pathways. Inflammation 46, 342–358 (2023). https://doi.org/10.1007/s10753-022-01737-7
2. Mashreghi M, Bayrami Z, Sichani NA, et al. An in vivo investigation on the wound-healing activity of Specific ligand for the innate repair receptor, ARA290, using a diabetic animal model. Research Square; 2023. DOI: 10.21203/rs.3.rs-2520194/v1.